Abstract
This work deals with a wide range of treatment options for patients with stage III non-small cell lung cancer (NSCLC). The article discusses the possibilities of surgical solutions, where it points to the irreplaceable role of a multidisciplinary team, especially in patients with positive lymph nodes of category N2.
In this part, the possibilities of neoadjuvant / adjuvant chemotherapy or immunotherapy are also discussed. The issue of postoperative radiotherapy is also discussed.
In patients who are not suitable for resection, the work deals with the reasons for the preference for concomitant over sequential chemoradiotherapy. Furthermore, the article discusses the addition of durvalumab as a consolidation therapy and some issues related to immunotherapy in this context.
The last part is devoted to targeted treatment in patients with stage III NSCLC, especially the study with adjuvant administration of osimertinib.